Although FDA’s timeframe for implementing a suffix-based nonproprietary naming system for licensed biological products remains a big unknown, the process is expected to take far more time than did the safety-related name changes for some botulinum toxin drug products several years ago.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?